Veru
Veru Inc. is a late clinical-stage biopharmaceutical company developing enobosarm, a SARM to preserve lean mass during GLP-1 obesity therapy, and sabizabulin, a broad anti-inflammatory for atherosclerotic coronary artery disease, while commercializing legacy products including the FC2 female condom.
- Company typePublic
- Founded1993
- HeadquartersMiami, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Veru does
Veru Inc. (NASDAQ: VERU) is a Miami-headquartered, late clinical-stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. Originally founded in 1993 as The Female Health Company and rebranded Veru Inc., the company operates as a publicly traded Florida corporation with 101-250 employees and a footprint spanning the United States, the United Kingdom, and Malaysia through wholly-owned legacy subsidiaries. The company has fully pivoted its strategic focus toward two clinical-stage drug candidates: enobosarm, a novel oral selective androgen receptor modulator (SARM) intended to preserve lean mass, physical function, and bone density in older patients (age 65+, BMI 35+) undergoing GLP-1 receptor agonist therapy for obesity; and sabizabulin, a novel oral broad anti-inflammatory agent targeting atherosclerotic coronary artery disease.
The underlying technology is built on small-molecule receptor pharmacology rather than biologics or platform technologies. Enobosarm is protected by composition-of-matter and method-of-use patents extending to 2046, providing a long exclusivity runway, and the FDA has clarified acceptable primary endpoints (weight loss, physical function, or bone mineral density) for registration. Sabizabulin's broad anti-inflammatory mechanism is positioned as differentiated versus standard-of-care cardiovascular therapies. The company additionally retains legacy commercial products — FC2 Female/Internal Condom (medical device), PREBOOST/Roman Swipes (consumer health), and ENTADFI (benign prostatic hyperplasia) — which historically generated approximately $16.89 million in revenue but have been de-emphasized as capital and management attention has shifted to the clinical pipeline. The lead value-creating catalyst is the Phase 2b PLATEAU trial of enobosarm plus semaglutide, which enrolled its first patient in March 2026, with interim analysis expected in Q1 2027 and topline data in Q4 2027.
Veru's business model is currently that of a pre-revenue clinical developer funded primarily by repeated post-IPO equity issuances rather than commercial product sales. The company has raised approximately $81.4 million across three public offerings in December 2023 ($33 million), October 2025 ($25 million), and December 2025 ($23.4 million), supported by a shelf Form S-3 registration filed in April 2026 to preserve capital-raising flexibility. Cash stood at $33.0 million as of December 31, 2025 and $27.6 million as of March 31, 2026 (up from $15.8 million at September 30, 2025), giving roughly one to two years of runway at current burn. Go-to-market upon any approval would rely on standard pharmaceutical distribution — wholesale distributors, retail pharmacies, and direct-to-provider channels — but the company does not yet have a commercial sales infrastructure in place. Institutional ownership is approximately 47.2% and a consensus analyst price target of $22.50 implies significant equity optionality tied to clinical readouts rather than current cash flows.
Veru firmographics
Firmographics- Name
- Veru
- Legal name
- Veru Inc.
- Website
- https://verupharma.com
- Company type
- Public
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Veru Inc. is a late clinical-stage biopharmaceutical company developing enobosarm, a SARM to preserve lean mass during GLP-1 obesity therapy, and sabizabulin, a broad anti-inflammatory for atherosclerotic coronary artery disease, while commercializing legacy products including the FC2 female condom.
- Ownership category
- akta.pro rank
Veru industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Veru is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Veru business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development and Commercialization: Pre-revenue late clinical stage biopharmaceutical company. Currently developing drugs in clinical trials with no approved products generating revenue. The company had $16.89 million in revenue as mentioned in one source (likely from existing products like FC2 female condom or other legacy products).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Veru product offering
Product offeringCore offering
Veru Inc. is a late clinical-stage biopharmaceutical company developing novel oral medicines for cardiometabolic and inflammatory diseases. Its lead drug candidates are enobosarm, a selective androgen receptor modulator (SARM) intended to preserve lean mass and physical function in patients undergoing GLP-1 weight loss therapy, and sabizabulin, an oral broad anti-inflammatory agent for atherosclerotic coronary artery disease. The company also manufactures and sells legacy consumer health products including the FC2 Female/Internal Condom and PREBOOST medicated wipes.
Product overview
Veru Inc. is a late clinical stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. The company's product portfolio consists of two main drug candidates in development: enobosarm (a SARM) for obesity treatment in combination with GLP-1 therapies, and sabizabulin (a broad anti-inflammatory) for atherosclerotic coronary artery disease. Additionally, the company manufactures and commercializes consumer health products including the FC2 Female/Internal Condom device and PREBOOST medicated wipes for premature ejaculation. The company is also developing enobosarm in combination with semaglutide (Wegovy) in the Phase 2b PLATEAU clinical trial targeting older patients with obesity.
Differentiator
Problem solved
Functional benefit
Brands
- FC2 Female Condom: Internal/female condom product for protection during sexual intercourse
- FC2 Internal Condom
- Preboost
- Roman Swipes
- ENTADFI
- enobosarm
- sabizabulin
Products and services
- Enobosarm A novel, oral, selective androgen receptor modulator (SARM) being developed to preserve lean mass, improve physical function, and maintain bone density while enhancing fat loss when combined with GLP-1 receptor agonists in patients undergoing weight loss therapy.
- Sabizabulin A novel, oral broad anti-inflammatory agent being developed to treat atherosclerotic coronary artery disease by addressing cardiometabolic inflammation.
- FC2 Female/Internal Condom A female/internal condom medical device for contraception and protection against sexually transmitted infections, manufactured, marketed, promoted, and distributed by Veru.
- PREBOOST (Roman Swipes) Medicated individual wipes marketed under the Roman Swipes brand for the prevention of premature ejaculation.
- ENTADFI A pharmaceutical product trademark held by the company, indicated for benign prostatic hyperplasia.
Quantifiable outcome
- Phase 2b QUALITY study showed enobosarm preserved lean mass while augmenting fat loss during active weight reduction therapy
- +1 more outcomes
Companies that use Veru
Customer profileSegments2 records
Ideal customer profiles3 records
Veru technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Veru partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights5 records
Veru competitors and assessment
Company assessmentEmerging players
- Structure Therapeutics: Clinical-stage company developing oral GLP-1 agonists (GSBR-1290) for obesity and diabetes. Comparable in obesity drug development focus and stage, with a complementary rather than directly competitive mechanism to enobosarm's muscle-preservation angle.
- Soleno Therapeutics: Late-stage biopharma developing DCCR (extended-release diazoxide) for Prader-Willi syndrome, a rare obesity disorder. Comparable small-cap clinical biopharma in obesity-adjacent metabolic indications.
Direct peers
- Axsome Therapeutics: Late-stage CNS-focused biopharma that has successfully launched novel therapeutics (Auvelity, Sunosi). Comparable small/mid-cap clinical biopharma with similar transition from clinical development to commercialization.
- Viking Therapeutics: Late-stage clinical biopharma developing VK2735, an injectable and oral GLP-1/GIP agonist for obesity. Most directly comparable to Veru as another small-cap obesity-focused drug developer with similar pipeline stage and market positioning.
- Madrigal Pharmaceuticals: Cardiometabolic specialty pharma that developed and commercialized resmetirom (Rezdiffra) for MASH/NASH. Comparable late-stage cardiometabolic developer with similar market cap profile and clinical-to-commercial transition.
- Esperion Therapeutics: Cardiometabolic specialty pharma with commercial cardiovascular products (Nexletol, Nexlizet) for LDL lowering. Comparable cardiometabolic focus with similar size and late-stage-to-commercial positioning.
- Crinetics Pharmaceuticals: Late clinical-stage endocrinology-focused biopharma developing paltusotine for acromegaly and an oral obesity candidate. Comparable small-cap clinical biopharma pursuing endocrine/metabolic indications with similar size and stage.
Broad incumbents
- Novo Nordisk: Market leader for GLP-1 therapy with Wegovy (semaglutide) and Ozempic, the drug being combined with enobosarm in the PLATEAU trial. Defines the addressable market opportunity and competitive backdrop.
- Innoviva: Specialty pharma holding company with royalty/development interests in infectious disease and critical care. Comparable small-cap specialty pharma with diversified therapeutic focus and similar market cap profile.
- Eli Lilly: Market leader for GLP-1 obesity therapy with Zepbound (tirzepatide). Relevant incumbent defining the obesity treatment paradigm that enobosarm is designed to complement with muscle preservation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Veru social profiles
Digital presenceVeru financial estimates
Financial estimateRevenue estimate
Valuation estimate
Veru leadership team
Management profileNumber of profiles
Profiles9 records
Veru subsidiaries and ownership
Company hierarchySubsidiaries4 records
Veru funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Veru M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Veru
What does Veru do?
Veru Inc. is a late clinical-stage biopharmaceutical company developing novel oral medicines for cardiometabolic and inflammatory diseases. Its lead drug candidates are enobosarm, a selective androgen receptor modulator (SARM) intended to preserve lean mass and physical function in patients undergoing GLP-1 weight loss therapy, and sabizabulin, an oral broad anti-inflammatory agent for atherosclerotic coronary artery disease. The company also manufactures and sells legacy consumer health products including the FC2 Female/Internal Condom and PREBOOST medicated wipes.
Is Veru a public or private company?
Veru is a public company. It is classified as public and is currently operating.
When was Veru founded?
Veru was founded in 1993. It employs 101 to 250 people.
Where is Veru based?
Veru is headquartered in Miami, United States, in the North America region.
How does Veru make money?
One revenue line is on record: pharmaceutical Development and Commercialization.
Who are Veru's main competitors?
Emerging players on record are Structure Therapeutics and Soleno Therapeutics. Direct peers are Axsome Therapeutics, Viking Therapeutics, Madrigal Pharmaceuticals, Esperion Therapeutics and Crinetics Pharmaceuticals. Broad incumbents are Novo Nordisk, Innoviva and Eli Lilly.
Does Veru have an API?
No public API is recorded for Veru.
What industry is Veru in?
Veru's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325414 and its SIC code is 2834.